-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific S
Amarin ( NASDAQ:AMRN ) Full Year 2023 Results Key Financial Results Revenue: US$306.9m (down 17% from FY 2022). Net...
It's been a sad week for Amarin Corporation plc ( NASDAQ:AMRN ), who've watched their investment drop 11% to US$1.06 in...